Steroids and the management of macular edema

Ophthalmologica

Volumn 224, Issue SUPPL. 1, 2010, Pages 31-40

  Golan, Shani ^a,b   Loewenstein, Anat ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Macular edema; Steroids

Indexed keywords

ANTIGLAUCOMA AGENT; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; ILUVEIN; INTERLEUKIN 6; RANIBIZUMAB; STEROID; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARGON LASER; BACTERIAL ENDOPHTHALMITIS; BLOOD RETINA BARRIER; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOPHTHALMITIS; EYE PAIN; GLAUCOMA; HUMAN; IMPLANT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; LOW DRUG DOSE; NONINFECTIOUS ENDOPHTHALMITIS; PSEUDOENDOPHTHALMITIS; PSEUDOPHAKIA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; TRABECULECTOMY; TREATMENT DURATION; TREATMENT INDICATION; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

CELL PROLIFERATION; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77955794739     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315159     Document Type: Review

References (73)

1. Tranos PG, Wickremasinghe SS, Stangos NT, et al: Macular edema. Surv Ophthalmol 2004; 49: 470-490.
2. Stanbury RM, Graham EM: Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 1998; 82: 704-708.
3. Cheng CK, Berger AS, Pearson PA, et al: Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci 1995; 36: 442-453.
4. Jaffe GJ, Ben-Nun J, Guo H, et al: Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107: 2024-2033.
5. Noma H, Funatsu H, Yamasaki M, et al: Pathogenesis of macular oedema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140: 256-261.
6. Adamis AP, Miller JW, Bernal MT, et al: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450.
7. Cohen T, Nahari D, Cerem LW, et al: Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736-741.
8. Cunha Vaz DJ : The blood-retinal barriers. Doc Ophthalmol 1976; 41: 287-327.
9. Vane J, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987; 1: 89-96.
10. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94: 761-774.
11. Lee CM, Olk RJ: Modified grid laser photocoagulation for diffuse diabetic macular oedema: long-term visual results. Ophthalmology 1991; 98: 1594-1602.
12. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/ grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1459.
13. Cunningham ET Jr, Adamis AP, Altaweel M, et al; Macugen Diabetic Retinopathy Study Group: A phase II randomized doublemasked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757.
14. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al; Pan-American Collaborative Retina Study Group: Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114: 743-750.
15. Yilmaz T, Weaver CD, Gallagher MJ, et al: Intravitreal triamcinolone acetonide for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009; 116: 902-911.
16. Jonas JB, Degenring RF, Kreissig I, et al: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-598. (Pubitemid 41108858)
17. Gillies MC, Sutter FK, Simpson JM, et al: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533-1538.
18. Gillies MC, Simpson JM, Gaston C, et al: Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009; 116: 2182-2187.
19. Jonas JB, Harder B, Kamppeter BA: Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004; 138: 970-977.
20. Kuppermann BD, Dugel P, Williams G, et al: A comparison of applicator versus incisional placement of the dexamethasone sustainedrelease drug delivery system. Paper presented at the American Academy of Ophthalmology, Chicago, 2005.
21. Kuppermann BD: Steroid implant overview: I-vation TA, Posurdex, Iluvien, and more. Paper presented at the American Academy of Ophthalmology, San Fransisco, 2009.
22. Gupta S, Boyer DS, Faber D, et al: Open-label phase 2 study of dexamethasone intravitreal implant for treatment of diabetic macular edema (DME) in vitrectomized patients: INTERIM results (E-abstract 4261/D927). ARVO, Fort Lauderdale, 2010. http://www. abstractsonline.com/Plan/ViewAbstract. aspx?sKey=8238cb2f-9c0c-47e3-bc25-f78ff1-ccb2ea&cKey=406192c9-eee7-4ea2- b6d9-ed1c67705c7c&mKey=%7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d.
23. Dugel PU, Eliott D, Cantrill HL, et al: I-vation TM TA: 24-month clinical results of the phase I safety and preliminary efficacy study (E-abstract 4332). ARVO, Fort Lauderdale, 2009. http://arvo.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=28c99cb6-1ce6-46fd-a6b5-0feb778502e7&cKey= b3024086-a8a5-418f-a9f1-e22c41389e45.
24. Campochiaro PA, Hafiz G, Shah SM, et al: Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010, E-pub ahead of print.
25. Campochiaro PA: Data from FAME phase 3 study for Iluvien presented at Angiogenesis 2010. 2010. http://www.news-medical.net/ news/20100304/Data-from- FAME-Phase-3-study-for-Iluvien-presented-at-Angiogenesis-2010.aspx.
26. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A: Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996; 80: 332-336.
27. McCluskey PJ, Towler HM, Lightman S: Management of chronic uveitis. BMJ 2000; 320: 555-558.
28. Young S, Larkin G, Branley M, Lightman S: Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001; 29: 2-6.
29. Das-Bhaumik RG, Jones NP: Low-dose intraocular triamcinolone injection for intractable macular oedema and inflammation in patients with uveitis. Eye 2006; 20: 934-937.
30. Whitcup SM, Lightman S, Belfort R, et al: Double-masked, sham-controlled, randomized study of dexamethasone intravitreal implant for the treatment of uveitis (E-abstract 6381). ARVO, Fort Lauderdale, 2010. http:// www.abstractsonline.com/Plan/ViewAbstract. aspx?sKey=c071b475-3d59-4591-9bce- 6ee0f5030dab&cKey=7f80a0a3-3509-4f4f-a542-efa1c3ecda09&mKey=%7b 1EA90E66-C548-49E0-9F05-30DA7938 D511%7d.
31. Pavesio C, Zierhut M, Bairi K, et al: Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010; 117: 567-575.
32. Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271-282.
33. Chen SD, Sundaram V, Lochhead J, Patel CK: Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006; 141: 876-883.
34. McAllister IL, Vijayasekaran S, Chen SD, Yu DY: Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009; 47: 838-846.
35. Scott IU, Ip MS, VanVeldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128.
36. Haller JA: Posurdex retinal vein occlusion phase 3 trials. Paper presented at the American Academy of Ophthalmology, San Fransisco, 2009.
37. Haller JA, Bandello F, Jiao J, et al: 12-month evaluation of dexamethasone intravitreal implant in patients with macular edema due to branch retinal vein occlusion (E-abstract 2439/D1035). ARVO, Fort Lauderdale, 2010. http://www.abstractsonline.com/Plan/View Abstract.aspx?sKey=86ffbbd1-7396-4af8- ac 3e-211c2f4a893c&cKey=ef7cafe0-216b-4231-a278-f24cf2068661&mKey= %7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d.
38. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M Report. Ophthalmology 1995; 102: 1425-1433.
39. Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-491.
40. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 782-783.
41. Park CH, Jaffe GJ, Fekrat S: Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136: 419-425.
42. Williamson TH, O'Donnell A: Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005; 139: 860-866.
43. Ip MS, Scott IU, VanVeldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-1114.
44. Bandello F, Blumenkranz MS, Jiao J, et al: 12-month evaluation of dexamethasone intravitreal implant in patients with macular edema due to central retinal vein occlusion (E-abstract 6397). ARVO, Fort Lauderdale, 2010. http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=5d7fa90f-c959-4b6f- 88a3-6200cb0c5896&cKey=3f5f153aa5bb-41b9-a3c3-5d70fa5d07cb&mKey= %7b1EA90E66-C548-49E0-9F05-30DA 7938D511%7d.
45. Belfort R Jr, Heier JS, Haller JA, et al: Benefits of early treatment with dexamethasone intravitreal implant in patients with macular edema due to BRVO or CRVO over 12 months (E-abstract 6398). ARVO, Fort Lauderdale, 2010. http://www.abstractsonline. com/Plan/ViewAbstract.aspx?sKey=5d 7fa90f-c959-4b6f-88a3-6200cb0c5896&cKey=8b4cd528-5270-4fb1-bfd5-5ad9ffb 89307&mKey=%7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d.
46. Challa JK, Gillies MC, Penfold PL, et al: Exudative macular degeneration and intravitreal triamcinolone: 18-month follow-up. Aust NZ J Ophthalmol 1998; 26: 277-281.
47. Danis RP, Ciulla TA, Pratt LM, et al: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-250.
48. Loewenstein A, Kuppermann BD, Weinberge D, et al: Safety and efficacy of Ozurdex TM (dexamethasone intravitreal implant) as adjunctive therapy to Lucentis in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (E-abstract 1255). ARVO, Fort Lauderdale, 2010. http://www.abstractsonline. com/Plan/ViewAbstract.aspx?sKey c47c76c1-a90e-4226-bc53-2686e5d1f306 &cKey=9626c362-ef58-4fc3-882f-96a 624366490&mKey=%7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d.
49. Martinez JA: Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 2003; 121: 1658-1659.
50. Saraiva VS, Sallum JM, Farah ME: Treatment of cystoid macular oedema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2003; 34: 398-400.
51. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003; 136: 384-386. (Pubitemid 36904101)
52. Sutter FK, Gillies MC: Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol 2003; 121: 1491-1493.
53. Scott IU, Flynn HW Jr, Rosenfeld PJ: Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol 2003; 136: 737-739.
54. Kragballe K: Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh) 1989; 151: 7-10.
55. Amsterdam A, Tajima K, Sasson R, et al: Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem Pharmacol 2002; 64: 843-850. (Pubitemid 35232258)
56. Tamura H, Miyamoto K, Kiryu J, et al: Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46: 1440-1444.
57. del Maschio A, Zanetti A, Corada M, et al: Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol 1996; 135: 497-510.
58. Itakura H, Akiyama H, Hagimura N, et al: Triamcinolone acetonide suppresses interleukin-1 -mediated increase in vascular endothelial growth factor expression in cultured rat Müller cells. Graefes Arch Clin Exp Ophthalmol 2006; 244: 226-231.
59. Nauck M, Roth M, Tamm M, et al: Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down-regulated by corticosteroids. Am J Respir Cell Mol Biol 1998; 16: 398-406.
60. Hayashi K, Hayashi H: Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2005; 139: 972-978.
61. Berger AS, Cheng CK, Pearson PA, et al: Intravitreal sustained-release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1996; 37: 2318-2325.
62. Tano Y, Sugita G, Abrams G, et al: Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 1980; 89: 131-136.
63. Beer PM, Bakri SJ, Singh RJ, et al: Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110: 681-686.
64. Inoue M, Takeda K, Morita K, et al: Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004; 138: 1046-1048.
65. Spada C, Lin T, Jackson B, et al: Posurdex inhibits retinal vasculopathy and neuropathy induced by intravitreal vascular endothelial growth factor (VEGF) in monkeys. Paper presented at the Association for Research into Vision and Ophthalmology, Florida, 2005.
66. Williams GA, Kuppermann BD, Blumenkranz MS, et al: Treatment of inflammatory edema with a dexamethasone posterior segment drug delivery system (Posurdex). Paper presented at the Association for Research into Vision and Ophthalmology, Florida, 2005.
67. Fluocinolone acetonide ophthalmic - Bausch & Lomb: fluocinolone acetonide Envision TD implant. Drugs R D 2005; 6: 116-119.
68. Jaffe GJ, Yang CH, Guo H, et al: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41: 3569-3575.
69. Jonas JB, Degenring RF, Kreissig I, et al: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-598. (Pubitemid 41108858)
70. Gillies MC, Simpson JM, Billson FA, et al: Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336-340.
71. Cekic O, Chang S, Tseng JJ, et al: Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005; 139: 993-998.
72. Jonas JB, Kreissig I, Degenring RF: Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye 2004; 18: 361-364. (Pubitemid 38585008)
73. Moshfeghi DM, Kaiser PK, Scott IU, et al: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791-796.